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Abstract
Genetic hypercalciuric stone-forming (GHS) rats have increased intestinal Ca absorption, decreased renal tubule Ca
reabsorption and low bone mass, all of which are mediated at least in part by elevated tissue levels of the vitamin D
receptor (VDR). Both 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and bone morphogenetic protein 2 (BMP2) are critical for
normal maintenance of bone metabolism and bone formation, respectively. The complex nature of bone cell regulation
suggests a potential interaction of these two important regulators in GHS rats. In the present study, BMP2 expression is
suppressed by the VDR-1,25(OH)2D3 complex in Bone Marrow Stromal Cells (BMSCs) from GHS and SD rat and in UMR-106
cell line. We used chromatin immunoprecipitation (ChIP) assays to identify VDR binding to only one of several potential
binding sites within the BMP2 promoter regions. This negative region also mediates suppressor reporter gene activity. The
molecular mechanisms underlying the down-regulation of BMP2 by 1,25(OH)2D3 were studied in vitro in BMSCs and UMR106 cells using the DNA methyltransferase inhibitor 5-aza-29-deoxycytidine (DAC) and the histone deacetylase inhibitor
trichostatin A (TSA). Both DAC and TSA activate BMP2 expression in combination with 1,25(OH)2D3. Bisulfite DNA
pyrosequencing reveals 1,25(OH)2D3 to completely hypermethylate a single CpG site in the same BMP2 promoter region
identified by the ChIP and reporter gene assays. ChIP assays also show that 1,25(OH)2D3 can increase the repressive histone
mark H3K9me2 and reduce the acetylation of histone H3 at the same BMP2 promoter region. Taken together, our results
indicate that 1,25(OH)2D3 binding to VDR down-regulates BMP2 gene expression in BMSCs and osteoblast-like UMR-106
cells by binding to the BMP2 promoter region. The mechanism of this 1,25(OH)2D3-induced transcriptional repression of
BMP2 involves DNA methylation and histone modification. The study provides novel evidence that 1,25(OH)2D3 represses
bone formation through down-regulating BMP2 expression both in vivo and in vitro.
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1,25(OH)2D3, the biologically active metabolite of vitamin D,
regulates gene expression in many tissues via binding to its
corresponding intra-nuclear receptor, VDR, a member of the
steroid hormone receptor superfamily [13]. 1,25(OH)2D3 functions in a variety of biological processes such as calcium
homeostasis, cell proliferation and cell differentiation [14]. In
particular, it is a critical regulator of bone turn-over [15,16]. It is
widely accepted that vitamin D is vital to bone growth, as its
deficiency can result in rickets and osteomalacia [17]. Previous
studies have demonstrated that 1,25(OH)2D3 increases bone mass
in vivo [18,19] and enhances the functional activity of mature
osteoblasts in vitro [20]. However, the physiological significance of
vitamin D is not without controversy. In VDR knockout mice,
vitamin D administration reportedly down-regulated bone formation [21,22]. Phex, a marker of the mature osteoblasts, and Runx2,
a key regulator of bone formation in vivo, were down-regulated by
1,25(OH)2D3 [23–25]. Recent research suggests that a daily
regimen of exogenous 1,25(OH)2D3 inhibits the BMP2 induced

Introduction
Hypercalciuria in both Genetic Hypercalciuric Stone-forming
(GHS) rats and patients with idiopathic hypercalciuria (IH), arises
from intestinal Ca hyperabsorption, increased bone resorption,
and decreased renal tubule Ca reabsorption [1–4]. As a result, the
urine is supersaturated with respect to calcium and oxalate and
calcium phosphate and therefore is predisposed to kidney stones of
calcium salts. Low bone mass is also found in both GHS rats [5]
and patients with IH [6,7], but the pathogenesis of the bone
disease is incompletely known. In previous studies, we have
reported high levels of VDR in GHS rat intestine, kidney and
BMSCs, which can account for all of the changes in calcium
metabolism that lead to hypercalciuria [8–11]. BMP2 is essential
for bone formation [12], and BMP2 gene expression is lower in
bone cells, kidney and intestine of GHS rats. Thus, we hypothesize
that VDR down-regulates BMP2 expression which in turn
contributes to low bone mass in GHS rats.
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Table 1. Putative VDREs regions and corresponding primers used in ChIP assays.

Region

Putative VDRE

Start

End

A

CACTCCATGTGACCT

121365229

121365243

Primer sequences
59-TTTCCTCAGCACGTCTTCCTCACT -39
59-AGCCTGCCTGAAGAAGAGTGGATT -39

B

TGACCTACTTGCTCC

121367554

121367568

59-CAGGGAGCACAGATCATTGGGAAT -39
59-TTCGGGAGAGCAAAGAGTTGCTGA -39

C

CGCCCCGCCCCGCCCCG

121371437

121371453

59-ATTTGCCCTAAACTCGGGCATCTG -39
59- TTCGTCCCGAGCTGCCAAT-39

D

AGGTCACCCGGTTTG

121372034

121372048

59- AGCACAGTCTTACCCTCAACGCT-39
59- GCATCCCTCAGCCTGACTCT-39

E

AGAGCAAATGGTGTG

121382425

121382439

59-CCCGTGAGAGCAAATGGTGTGTTT -39
59-CCTTGAGTTCTGCACGCTTTGCTT -39

F

TACACTGTATAACCT

121384896

121384910

59-GTGTGATGTCAGTGCCAAGCATCT -39
59-CTTTGCAGAGGGAAACCCATTCCT -39

G

TGCACTGGTCAAACT

121390091

121390105

H

AGTGTACCCAGAGTG

121390193

121390207

59-AGGGACCAGATTATGCACAGACCA -39
59-AAATGGAGCGAATCTCTGCCTCTG -39

The start and end nucleotide positions are based on the Rat genome assembly version Baylor 3.4/rn4. Region G and Region H share one primer pair.
doi:10.1371/journal.pone.0061423.t001

signaling pathway in vitro, thus effectively suppressing bone
mineralization [26]. Despite the ongoing controversy, the detailed
mechanisms of 1,25(OH)2D3 in bone formation have yet to be
clarified.
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-b (TGF-b) superfamily and were first identified
by their ability to initiate osteogenic differentiation [27,28]. BMP2,
one of the most well characterized BMPs, is an osteogenic factor

that may stimulate osteoblast differentiation and osteogenic nodule
formation in vitro, as well as bone formation in vivo [29,30]. It is
a key mediator of bone development and repair [31–33] and is
required for fracture healing [34]. BMP2 plays a central role in
initiating and regulating bone formation, so any factors that
regulate the expression of BMP2 would be expected to influence
bone formation.

Figure 1. VDR levels and BMP2 expressions in GHS and SD rats. Nuclear proteins were isolated from BMSCs and tissues of SD and GHS rats
and were subjected to Western blot using anti VDR. The representative data are shown in (A). Expressions of BMP2 in BMSCs, kidney and intestine
tissues from GHS rats decrease relative to SD rats (B, C, D). (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0061423.g001
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Figure 2. Repression of BMP2 by 1,25(OH)2D3. A. qRT-PCR of BMP2 expression in BMSCs from SD rats at several time points treated with
1028 mol/L 1,25(OH)2D3. B. qRT-PCR of BMP2 expression in BMSCs from SD rats treated with a range of concentrations of 1,25(OH)2D3. C. qRT-PCR of
BMP2 expression in BMSCs from GHS rats treated with 1028 mol/L 1,25(OH)2D3 at different points in time. D. qRT-PCR of BMP2 expression in BMSCs
from GHS rats treated with step-wise concentrations of 1,25(OH)2D3. E. qRT-PCR of BMP2 expression in UMR-106 cells treated with 1028 mol/L
1,25(OH)2D3 at multiple time points. F. qRT-PCR of BMP2 expression in UMR-106 cells treated with varying concentrations of 1,25(OH)2D3. (*, P,0.05;
**, P,0.01).
doi:10.1371/journal.pone.0061423.g002

Based on our current data, 1,25(OH)2D3 has both positive and
negative regulatory functions in bone formation. However, the
interaction between 1,25(OH)2D3 and BMP2 is not fully known,
and further studies may reveal new biologic effects of 1,25(OH)2D3
on bone formation.

PLOS ONE | www.plosone.org

In the present study, we demonstrate that BMP2 expression is
down-regulated by 1,25(OH)2D3 in both BMSCs and UMR-106
cells through DNA methylation and histone modification. Our
results support the negative regulation of BMP2 expression by
1,25(OH)2D3.
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fetal bovine serum (FBS), 100 U/ml penicillin, and 100 ug/ml
streptomycin in a humidified 5% CO2 incubator at 37uC.
The UMR-106 cell line was obtained from American Type
Culture Collection (Manassas, VA) and cultured in the same
medium and conditions as the BMSCs. Cells were passed every 3–
4 days when approaching confluence using the fresh medium and
were not used beyond passage 15.

In Vitro Treatment
Cells were seeded into 6-well plates at 16106 cells/well for
24 hr and then the media were changed. For time-response trials,
BMSCs from GHS and SD rats were incubated with 1,25(OH)2D3
(Sigma, St Louis, MO) dissolved in ethanol at 1028 M for 6, 12
and 24 hr. Control cultures were administered with an equivalent
volume of 100% ethanol. UMR-106 cells were incubated with
1,25(OH)2D3 at 1028 M for 1, 6, 12, 24, 36 and 48 hr for the time
course experiments. For dose-response trials, cells were incubated
with 1,25(OH)2D3 at 1027, 1028 and 1029 M for 24 hr.
To determine the potential modulatory roles of DNA methylation and histone modification in BMP2 expression, BMSCs and
UMR-106 cells were cultured in the presence of DAC (Sigma, St
Louis, MO) at 0.5, 1.0 and 2.0 mM for 3 days, with or without the
addition of 1,25(OH)2D3 (1028 M) for an additional 24 hr. And
TSA (Sigma, St Louis, MO) was used to treat at 20, 100 and
500 nM for 8 hr, with or without a subsequent addition of
1,25(OH)2D3 (1028 M) for an additional 24 hr.

Figure 3. VDR binding to BMP2 promoter region in vitro. ChIP
assays were performed on UMR-106 cell extracts using anti-VDR
antibody with or without 1,25(OH)2D3 administration. Normal IgG was
used as a negative control. DNA was precipitated with either anti-VDR
antibody or normal IgG. The primer pairs of putative VDREs in rat BMP2
promoter region (as described in ‘‘Materials and Methods’’) were used
to amplify the ChIP DNA fragments. A. The site of BMP2 promoter
region C and the two corresponding promoters (22181 and 21452)
based on the conserved sequence data in mouse. B. The results showed
that VDR bind to BMP2 promoter region C.
doi:10.1371/journal.pone.0061423.g003

Western Blot
Nuclear extracts from BMSCs and rat tissues were isolated
using the Nuclear and Cytoplasmic Extraction kit (Pierce, Inc.,
Rockford, IL) according to the manufacturer’s directions. Protease
Inhibitor Cocktail (Sigma, St Louis, MO) was added into the
reagent prior to extraction. Protein concentrations were assessed
using DUH Series 500 (Beckman, Fullerton, CA). Nuclear proteins
were separated by 12% SDS-PAGE gel electrophoresis when they
were then transferred to nitrocellulose membranes using IBlot Gel
Transfer Stacks (Invitrogen, Grand Island, NY) and blotted with
anti-VDR (Enzo Life Sciences, Farmingdale, NY) and anti-b-actin
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The
blotted proteins were detected by an ECL Western Blotting kit
(Amersham Biosciences, Piscataway, NJ).

Materials and Methods
Animals
The colony of GHS rats was created by screening for
spontaneous hypercalciuria and then selectively breeding hypercalciuric male and female Sprague-Dawley (SD) rats (Harlan, Inc.,
Indianapolis, IN) [2]. The hypercalciuric offspring of the breedings
called GHS rats were raised at the University of Rochester and
shipped to the University of Chicago at 6–7 weeks of age with the
body weight in 220–250 g range. SD rats purchased from Harlan,
Inc. (Indianapolis, IN) were matched for age and body weight to
the GHS rats.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal experiments were approved by the University of Chicago
Institutional Animal Care and Use Committee.
GHS and SD rats were sacrificed by CO2 narcosis followed by
cervical dislocation. Tissues were removed, flash frozen in liquid
nitrogen, and then subjected to rapid protein isolation and RNA
extraction assays.

Total RNA Extraction and Quantitative Real-time PCR
Total RNA extraction was performed using TRIzol Reagents
(Invitrogen, Grand Island, NY). cDNA synthesis was performed
for 2 hr at 37uC with 1 ug of total RNA, using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad,
CA) according to the manufacturer’s directions. qRT-PCR was
performed using SYBR green master PCR mix (Applied
Biosystems, Carlsbad, CA). Gene expression of BMP2 was
normalized to that of GAPDH. PCR products were quantified
using the comparative cycle threshold (Ct) method as described
previously [36]. The primer sequences for rat BMP2 and GAPDH
were as follows: BMP2 (Forward) 59-CCT ATA TGC TCG ACC
TGT AC -39, (Reverse) 59-CCC ACT CAT TTC TGA AAG
TTC-39; GAPDH (Forward) 59-GCA CAG TCA AGG CTG AGA
AT-39, (Reverse) 59-TGA AGA CGC CAG TAG ACT CC -39.

Cell Culture
The BMSCs from long bones of GHS and SD rats were isolated
as previously described with only minor modifications [35].
Ammonium chloride solution (STEMCELL Technologies Inc.
Vancouver, Canada) was used to remove the red blood cells
according to the manufacturer’s directions. The BMSCs were
seeded into 6-well plates at 16106 cells/well and cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%

PLOS ONE | www.plosone.org

ChIP Assay
The ChIP assay was performed as previously described with
minor modifications [37]. The UMR-106 cells incubated with
drugs were cross-linked by adding 270 mL 37% formaldehyde into
10 ml mediums for 10 min. The cross-link was stopped by the
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Figure 4. Activation of BMP2 expression by DAC. A. qRT-PCR of BMP2 expression in BMSCs from SD rats treated with varying concentration of
DAC. B. qRT-PCR of BMP2 expression in BMSCs from SD rats treated with varying concentrations of DAC followed by 1,25(OH)2D3. C. qRT-PCR of BMP2
expression in BMSCs from GHS rats treated with varying concentrations of DAC. D. qRT-PCR of BMP2 expression in BMSCs from GHS rats treated with
varying concentrations of DAC followed by incubation with 1,25(OH)2D3. E. qRT-PCR of BMP2 expression in UMR-106 cells treated with varying
concentrations of DAC. F. qRT-PCR of BMP2 expression in UMR-106 cells treated with varying concentrations of DAC followed by 1,25(OH)2D3. G.
Bisulfate sequencing of BMP2 promoter CpG island methylation in UMR-106 cells with 1,25(OH)2D3 administration and the CpG response site. The
sequence is numbered relative to the translational start site. H. Antibody against H3K9me2 was used to do ChIP assay on chromatin extracted from
UMR-106 cells which were incubated with 1,25(OH)2D3 or vehicle. The normal IgG was used as a negative control. Primer pairs designed for BMP2
promoter region C were used in the PCR. (*, P,0.05; **,P,0.01).
doi:10.1371/journal.pone.0061423.g004

addition of 0.125 M glycine (final concentration). Cell lysates were
sonicated to shear DNA to an average length of 200 to 1000 bps.
VDR antibody (Enzo Life Sciences, Farmingdale, NY), antibody
against histone H3 dimethylated lysine 9 (H3K9me2) (Millipore,
Billerica, MA) and antibody against acetyl-histone H3 (Millipore,
Billerica, MA) were used to immunoprecipitate the DNA-protein
complexes, respectively. Normal IgG (Santa Cruz Biotechnology,
Santa Cruz, CA) was used as a negative control. After an overnight
incubation with the antibody, antibody/histone complexes were
collected by adding 80 mL of Protein A Agarose/Salmon Sperm
DNA (Millipore, Billerica, MA). The protein A agarose/antibody/
chromatin complexes were then washed with the following buffers
in the respective order (Millipore, Billerica, MA): low salt wash,
high salt wash, LiCl wash, and TE buffer. DNA acquired before
precipitation was used to assess the presence of genes following the
ChIP procedure and designated ‘‘Input’’. The DNA was eluted
with 1% SDS and 0.1 M NaHCO3 elution buffer, and then
subjected to reverse cross-linking and proteinase digestion.
Ultimately, the DNA fragments were purified using QIAquick
PCR Purification Kits (Qiagen, Valencia, CA) and subjected to
PCR.
The entire BMP2 and its flanking regions (a total of 28,545 bps)
were screened for putative VDR3-response elements (VDREs).
Only the most typical DR3 type consensus sequence was screened,
i.e. the direct repeat of the hexameric core sequence RGDKYR
(R = G or A, D = A, G or T, K = G or T, Y = C or T). We used the
online ‘‘DNA Pattern Find’’ program for the motif screening.
Finally, eight putative VDREs were identified and corresponding
primer pairs for detecting these loci were designed (Table 1).

Reporter Assays
The fragment of rat BMP2 promoter region (Region C)
containing the VDR binding site was generated by PCR using
primers Forward 59-ATTTGCCCTAAACTCGGGCATCTG-39
and Reverse 59- TTCGTCCCGAGCTGCCAAT-39 and was gelpurified with Gel Extraction Kit (Qiagen, Valencia, CA). The
fragment was first cloned into pCRH2.1 vector using the T-A
Cloning Kit (Invitrogen, Carlsbad, CA) and sequenced thereafter.
The plasmids containing region C were amplified and digested
with XhoI and KpnI (New England Biolabs, Ipswich, MA). The
target DNA fragment was then gel-purified as before and cloned
into the pGL3 Promoter Vector (Promega, madison, WI) which
contains an SV40 promoter upstream of the luciferase gene.
Subsequently, the constructed pSV40-BMP2 BR-Luciferase plasmid was transfected into the UMR-106 cells with Lipofectamine
2000 Reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s protocol. 24 hr after transfection, the cells were treated
with 1028 M 1,25(OH)2D3 for additional 24 hr and then were
lysed with Tropix Lysis Buffer (Applied Biosystems, Carlsbad, CA).
The luciferase and b-Galactosidase activities were measured using
the Luciferase & b-Galactosidase Reporter Gene Assay System
(Applied Biosystems, Carlsbad, CA) according to the manufacturer’s guidelines. b-Galactosidase activity was used to normalize
transfection efficiency.

Data Analysis
Statistical analysis was performed using the Student’s t-Test for
unpaired comparisons. Data were presented as means 6 SE, and
p,0.05 was considered significant.

Bisulfite DNA Pyrosequencing

Results

Genomic DNA was isolated using the Genomic DNA Isolation
Kit (Qiagen, Valencia, CA) from UMR-106 cells incubated with
1,25(OH)2D3 or vehicle. About 1 mg of rat genomic DNA was
treated with bisulfite conversion reagents using the MethylEasy
Xceed Rapid DNA Bisulfite Modification Kit (Human Genetic
Signatures, Australia) according to the manufacturer’s instruction.
The bisulfite converted genomic DNA was amplified using BMP2F1 (59-AGTGGGGGAATTTAGAGGTAAG-39) and BMP2-R1
(59-TATCRTACCRACCCCTCRAAACCCC-39) primers with
the following cycling condition: 95uC 3 min, then 30 cycles of
95uC 30 sec, 56uC 30 sec and 72uC 60 sec. About 2% of the PCR
products were subject to a second round of amplification using
nested primers BMP2-F2 (59-AGAGGTAAGTTTATTTTGAATTTG-39) and BMP2-R2 (59-CTTCRTCCCRAACTACCAATCCC-39) with the same PCR procedural condition as
above. The amplified PCR products were then subcloned; 25
clones from each ligation were randomly picked and sequenced on
an Applied Biosystems 3130 instrument. Fractional DNA methylation [#C/(#C+#T)] for each CpG site was determined based
on the number of times it was sequenced as a T or as a C.

VDR Levels and BMP2 Expression in GHS and SD Rats

PLOS ONE | www.plosone.org

VDR levels are higher in BMSCs from GHS rats compared to
SD rats (Figure 1A). Using qRT-PCR we found BMSCs from
GHS rats had a 20% lower BMP2 mRNA expressions (P,0.01)
compared to SD rats (Figure. 1B). Kidney and intestinal tissues of
GHS rats had higher VDR levels and lower BMP2 mRNA
expression compared to levels in the SD rat tissues (Figure. 1A and
C, D).

Effects of 1,25(OH)2D3 on BMP2 Expression
BMP2 mRNA expression in BMSCs was significantly downregulated in the presence of 1,25(OH)2D3 at 6, 12 and 24 hr in SD
(Figure. 2A) and GHS rats (Figure. 2C). In BMSCs, suppression of
BMP2 mRNA by 1,25(OH)2D3 was dose-dependent in both SD
(Figure. 2B) and GHS rats (Figure. 2D).
Using UMR-106 cells cultured with 1,25(OH)2D3 over 1–48 hr
created a time-dependent decrease in BMP2 mRNA levels
(Figure. 2E). A dose dependent down-regulation of BMP2
expression by 1,25(OH)2D3 also occurred in the UMR-106 cells
(Figure. 2F). At concentrations of 1029 M, 1028 M and 1027 M,
1,25(OH)2D3 reduced BMP2 mRNA to 55%, 25%, and 18% of
control levels, respectively (P,0.01).
6
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Figure 5. Histone modifications associated with BMP2 expression. A. qRT-PCR of BMP2 expression in BMSCs from SD rats treated with varying
concentrations of TSA. B. qRT-PCR of BMP2 expression in BMSCs from SD rats treated with varying concentrations of TSA followed by 1,25(OH)2D3. C.
qRT-PCR of BMP2 expression in BMSCs from GHS rats treated with varying concentrations of TSA. D. qRT-PCR of BMP2 expression in BMSCs from GHS
rats treated with varying concentrations of TSA followed by 1,25(OH)2D3. E. qRT-PCR of BMP2 expression in UMR-106 cells treated with varying
concentrations of TSA. F. qRT-PCR of BMP2 expression in UMR-106 cells treated with varying concentrations of TSA followed by 1,25(OH)2D3. G.
Antibody against acetyl-histone H3 was used to do ChIP assay on chromatin extracted from UMR-106 cells which were incubated with 1,25(OH)2D3
(together with or without TSA) or vehicle. The normal IgG was used as a negative control. Primer pairs designed for BMP2 promoter region C were
used in the PCR. (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0061423.g005

1,25(OH)2D3 incubation. Bisulfite pyrosequencing was performed
on the DNA fragment containing region C from UMR-106 cells
incubated in the presence of 1,25(OH)2D3 or vehicle. Of the
57 CpGs sparsely spaced in this region of DNA, one was
completely (100%, 25C/0T) methylated after incubation with
1,25(OH)2D3 (Figure. 4G). In the untreated control cell line, this
CpG site was not methylated (Data not shown). The results
indicate that 1,25(OH)2D3 represses BMP2 expression through
DNA methylation.
To clarify the role of histone methylation in 1,25(OH)2D3
induced regulation of the BMP2 gene, we examined the repressive
histone mark H3K9me2 associated with the BMP2 promoter
region using the ChIP assay. The result demonstrated that
H3K9me2 was increased in the BMP2 promoter region C in the
presence of 1,25(OH)2D3 in UMR-106 cells (Figure. 4H).

VDR Binding to Rat BMP2 Promoter Region
We identified eight putative VDR binding sites in BMP2
promoter region, including positions and sequences (Table 1).
Seven primer pairs were designed to match the putative binding
sites. The ChIP DNA fragments from the UMR-106 cells were
amplified via PCR. Significant binding of VDR to BMP2
promoter region C was identified in cells incubated with
1,25(OH)2D3 (Figure. 3B). The other putative sites showed no
binding to VDR (data not shown).

DNA Methylation Reduces BMP2 Gene Expression
BMSCs from SD and GHS rats were incubated with DAC,
a DNA methyltransferase inhibitor. 0.5 uM DAC up-regulated
BMP2 expression in BMSCs from SD rats (Figure. 4A). Consistent
up-regulation of BMP2 expression occurred in BMSCs from GHS
rats following DAC administration (Figure. 4C). When incubated
with 1,25(OH)2D3, higher concentrations (1.0 and 2.0 mM) of
DAC induced BMP2 expression in BMSCs from both SD and
GHS rats (Figure. 4B.D). The role of DNA methylation in
regulation of BMP2 expression was also explored in UMR-106
cells. In the presence of DAC, BMP2 expression is up-regulated in
UMR-106 cells. However, despite using a range of DAC
concentrations, no significant difference of BMP2 expression was
detected (Figure. 4E). Incubation with both DAC and
1,25(OH)2D3 stimulated a concentration-dependent induction of
BMP2 expression (Figure. 4F).
Bisulfite pyrosequencing was used to test the potential role of
DNA methylation in BMP2 expression down-regulated following

Histone Modification is Associated with BMP2 Expression
TSA, a histone deacetylase inhibitor, up-regulated BMP2
expression in BMSCs from SD rats (Figure. 5A) and only
20 nM TSA increased BMP2 expression in BMSCs from GHS
rats (Figure. 5C). With 1,25(OH)2D3, both 100 and 500 nM TSA
up-regulated BMP2 expression in BMSCs from SD and GHS rats.
The highest concentration increased BMP2 expression by more
than 10 times compared to 1,25(OH)2D3 administration alone
(Figure. 5B.D).
Using UMR-106 cells, TSA elicited a dose-dependent induction
of BMP2 expression which was dependent upon 1,25(OH)2D3. A
range of concentrations of TSA failed to change BMP2 expression
in a dose-dependent manner (Figure. 5E). When UMR-106 cells
were treated with either 100 or 500 nM TSA plus 1,25(OH)2D3,
BMP2 expression increased by 120% and 180%, respectively,
compared to 1,25(OH)2D3 administration alone (Figure. 5F).
Using the ChIP assay, we found that 1,25(OH)2D3 decreased
the acetylation of histone H3 obviously in the BMP2 promoter
region C in UMR-106 cells, but this deacetylation was not
reversed by the additional TSA treatment (Figure. 5G).

VDR Represses BMP2 Transcription through BMP2
Promoter Region C
We amplified the VDR binding region involving rat BMP2
promoter (region C) and constructed a pSV40-BMP2 BRLuciferase plasmid. The construct was transfected into UMR106 cells with the pCMV-bGal vector. Activity of the pSV40BMP2 BR-Luciferase promoter was reduced by 40% following
administration of 1,25(OH)2D3 (Figure. 6, P,0.05), whereas no
difference was noted in the pSV40-Luciferase promoter activity
(Figure. 6, P.0.05). These results indicate that VDR exerts its
repressive effect through site-specific binding to the region C
sequence.

Figure 6. Effect of the VDR binding region in the BMP2
promoter. Luciferase activity in UMR-106 cells after 24 hr transfection
with the construct pSV40-BMP2 BR-luciferase plasmid followed by
1,25(OH)2D3 or vehicle for an additional 24 hr is shown. The pGL3
Promoter Vector which contains an SV40 promoter upstream of the
luciferase gene was used as a negative control. (*, P,0.05).
doi:10.1371/journal.pone.0061423.g006
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Discussion
Pathologic changes in calcium metabolism including increased
calcium transport across intestine, bone and kidney which
characterize IH are also found in GHS rats [7,38,39]. Bone mass
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is low in both human IH and GHS rats. In GHS rats, the low bone
mineral density is due in part to both a decrease in trabecular
volume and thickness with a resulting increase in fragility [7]. The
cellular basis for the low bone mass in GHS rats is a defective
function in both osteoclastic bone resorption and osteoblastic bone
formation (unpublished data). In the present study, we found that
BMP2 expression is lower in BMSCs from GHS rats. BMP2 is
a key osteogenic factor that is responsible for stimulating
osteoblastic differentiation in BMSCs into mature osteoblasts
which are then capable of synthesizing and secreting proteins that
compose the bone matrix and ultimately stimulating bone growth.
Thus, reduced BMP2 expression in GHS rats is a major factor in
reducing bone mass. We also demonstrated the higher VDR levels
in GHS rat BMSCs. However, the interaction between VDR and
BMP2 is not fully known. In the present study, we found that
BMP2 gene expression is down-regulated by a direct action of
1,25(OH)2D3 when incubated in both BMSCs from SD and GHS
rats and UMR-106 cells. The inhibitory action appears to be cellspecific, as BMP2 expression was not changed by 1,25(OH)2D3
when incubated with two kidney cell lines HEK293 and RK3E
(data not shown). So the lower bone mass in GHS rats may have
been partly caused by the higher VDR levels which could repress
BMP2 expression.
Most if not all of the biological actions of 1,25(OH)2D3 require
binding to VDR followed by transcriptional regulation of a large
number of genes that are responsible for the biologic actions
associated with vitamin D [40,41]. VDR regulates target gene
expression by binding to specific DNA response elements [42]. In
the present study, we identified a novel VDR binding site in the
BMP2 promoter region. According to the previous report
[43],there are two conserved promoters initiating the BMP2
transcription in mouse. These regions are highly conserved
between mouse and rat. By matching the rat sequence to that of
mouse, we found that this novel VDR binding site is located at
about 170–180 bps upstream of the transcription start site of the
distal promoter region (Figure. 3A). One other study has
demonstrated two repressive regulatory elements located in the
BMP2 promoter and the upstream one localizes to the homologous
position with BMP2 promoter region C in our study [44]. Using
the luciferase assay, the BMP2 promoter region C mediates BMP2
gene repression following incubation with 1,25(OH)2D3. Therefore, the negative regulation of VDR on BMP2 gene expression is
mediated by VDR binding to the novel VDR binding site within
the rat BMP2 promoter region.
Besides ligand-induced transcriptional repression by VDR, we
observed co-regulator switching to be involved in the modulation
of BMP2 expression. DNA methylation is among those coregulators with its actions primarily at CpG sites. Approximately
70% of gene promoter regions are located within CpG islands
[45]. Methylation of CpG islands down-regulates gene expression
during development and differentiation [46–48]. In the present
study, there is a 59CpG-rich island in BMP2 promoter region C

which suggests a regulatory role of DNA methylation on BMP2
gene expression. Pyrosequencing revealed an entirely methylated
CpG in the BMP2 promoter region C following 1,25(OH)2D3
administration in UMR-106 cells. This strongly suggests that
1,25(OH)2D3 complexes with the VDR and promote repression
via methylation of the BMP2 promoter. Moreover, the DNA
methylation inhibitor up-regulated BMP2 expression and reversed
the suppression by 1,25(OH)2D3 in both BMSCs from SD and
GHS rats and UMR-106 cells. Furthermore, histone lysine
methylation plays a key regulatory role in gene expression.
Dimethylation of H3K9 is involved in transcriptional silencing and
it is the critical mark for DNA methylation [49,50]. In the current
study, the ChIP assay demonstrated that 1,25(OH)2D3 increased
the gene silence mark H3K9me2 in the BMP2 promoter region C.
Together, the results indicate that DNA methylation in the
promoter region contributes, at least in part, to transcriptional
down-regulation of BMP2 expression by 1,25(OH)2D3.
In addition to VDR-mediated regulation of BMP2 expression
through DNA methylation, histone acetylation may occur through
a reversible modification controlled by histone acetylases (HATs)
and histone deacetylases (HDACs) [51]. Acetylation of histones
opens the chromatin structure and promotes transcription [45].
Site-specific acetylation or deacetylation in the promoter regions
results in activation or repression of transcription, respectively
[52]. In the present study, there was no consistent effect by histone
deacetylation inhibitor alone on BMP2 expression in either the
BMSCs or UMR-106 cells. However, when the histone deacetylation inhibitor was added into the culture medium along with
1,25(OH)2D3, there was a concentration-dependent increase in
BMP2 expression. The ChIP assay demonstrated that
1,25(OH)2D3 reduced histone H3 acetylation specifically in the
BMP2 promoter Region C. However, TSA treatment did not
enhance histone H3 acetylation in the BMP2 promoter Region C
in the present study. This might be because TSA has multiple
effects on numerous gene expressions, which in turn directly or
indirectly affects the chromatin modification of BMP2 gene. Of
particular importance is the absence of acetylation of the histone
H3 in Region C in the presence of 1,25(OH)2D3. The results
strongly suggest that 1,25(OH)2D3 induces histone deacetylation
and so contributes to BMP2 repression.
In summary, the results presented suggest that 1,25(OH)2D3
down-regulates BMP2 gene expression in osteoblast-like cells by
activating a negative VDRE in the BMP2 promoter. High levels of
VDR mediate low bone mass in GHS rats partially through downregulation of BMP2 expression.
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